Latest Breaking News On - Merck sharpe - Page 24 : comparemela.com

Chinook Therapeutics Announces Update on Non-Renal Legacy Programs from Aduro Biotech Merger Van Herk Investments to Form and Invest in Sairopa, a New Company Focused on Research and Development of B-Select Monoclonal Antibody Platform Programs VANCOUVER, British Columbia and SEATTLE, April 05, 2021 (GLOBE NEWSWIRE) Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced a transaction with Van Herk Investments, a leading European life science investor, to create and fund a new company called Sairopa, with a pipeline focused on research and development of non-renal monoclonal antibodies generated through Aduro Biotech’s B-Select platform. Chinook will own approximately 40 percent of Sairopa after the first tranche of financing from Van Herk and have one seat on Sairopa’s Board of Directors.

United kingdomBritish columbiaTom frohlichVan herkNoopur liffickEli lillyZealand pharmaVan herk groepCompany lillyNovartis pharmaceuticals corporationChinook therapeutics incCompany focused on researchInvestor relations corporate communicationsMerck sharpe dohme corpVan herk investmentsNew company focused